National Vision Holdings (NASDAQ:EYE) reported second-quarter 2026 financial results with net revenue of $498.8 million, up 2.5%, and comparable store sales growth of 3.4% for the quarter ended July 4, 2026.
Eli Lilly and Company (NYSE:LLY) filed six lawsuits against U.S. businesses accused of selling black-market retatrutide products, while the company continues efforts to report illegal sales to regulators and law enforcement.
PodcastOne (NASDAQ:PODC) reported record first-quarter fiscal 2027 revenue of $16.1 million for the quarter ended June 30, 2026, up 8% year-over-year, with adjusted EBITDA increasing to $1.6 million.
DarioHealth (NASDAQ:DRIO) reported second-quarter 2026 revenue of $5.2 million, down about 4% year over year, while gross margin improved to 61.7%.
Eli Lilly (NYSE:LLY) received U.K. approval for Foundayo on August 10 for adult weight management and insufficiently controlled type 2 diabetes.
Hims & Hers Health (NYSE:HIMS) reported second-quarter 2026 revenue of $753.2 million, up 38% from $544.8 million a year earlier.
Cardinal Infrastructure Group (NASDAQ:CDNL) reported second-quarter 2026 revenue of $226.9 million, up 114% year over year, with approximately 64% organic growth.
Cardinal Health (NYSE:CAH) reported fiscal fourth-quarter 2026 revenue of $63.7 billion, up 6%, while GAAP operating earnings rose 70% to $729 million.
BioHarvest Sciences (NASDAQ:BHST) reported second-quarter 2026 revenue of $8.8 million, up 3.8%, while gross margin slipped to 58%.
Shattuck Labs (NASDAQ:STTK) reported a $15.2 million Q2 2026 net loss with no revenue while advancing lead candidate SL-325.
Organigram Global (NASDAQ:OGI) reported $145.1 million in third-quarter gross revenue alongside a net income of $105.5 million.
Philips (NYSE:PHG) raised Exor’s permitted ownership cap to 22% from 20% under an updated long-term relationship agreement.
